Search results for "Kinase"

showing 10 items of 2635 documents

Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination T…

2022

Background Drug-drug interactions are a major concern in oncology and may potentially affect the outcome of patients with cancer. Objective In this study, we aimed to determine whether the concomitant use of statins, metformin, or proton pump inhibitors affects survival in patients with metastatic renal cell carcinoma treated with first-line combination therapies. Methods Medical records of patients with documented metastatic renal cell carcinoma between January 2016 and November 2021 were reviewed at 17 participating centers. This research was conducted in ten institutions, including both referral centers and local hospitals. Patients were assessed for overall survival, progression-free su…

Vascular Endothelial Growth Factor ACancer ResearchAngiogenesis InhibitorsProton Pump InhibitorsKidney NeoplasmsMetforminTreatment OutcomeOncologyHumansPharmacology (medical)Hydroxymethylglutaryl-CoA Reductase InhibitorsCarcinoma Renal CellProtein Kinase InhibitorsRetrospective StudiesTargeted oncology
researchProduct

Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.

2020

Abstract Progression on therapy in non-small cell lung carcinoma (NSCLC) is often evaluated radiographically, however, image-based evaluation of said therapies may not distinguish disease progression due to intrinsic tumor drug resistance or inefficient tumor penetration of the drugs. Here we report that the inhibition of mutated EGFR promotes the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the cells become resistant with a mesenchymal phenotype. As EDN1 and its receptor (EDNR) is linked to cancer progression, EDNR-antagonists have been evaluated in several clinical trials with disappointing results. These trials were based on a hypothesis that…

Vascular Endothelial Growth Factor ACancer ResearchLung NeoplasmsAmbrisentanOncology and CarcinogenesisDrug ResistanceBiological AvailabilityAntineoplastic AgentsDrug resistanceCell LineMiceErlotinib HydrochlorideGefitinibIn vivomedicineAnimalsHumansOncology & CarcinogenesisNon-Small-Cell LungProtein Kinase InhibitorsLungCancerTumor microenvironmentTumorEndothelin-1business.industryCarcinomaLung CancerCancerEvaluation of treatments and therapeutic interventionsGefitinibmedicine.diseaseEndothelin 1Xenograft Model Antitumor AssaysErbB ReceptorsOncologyVasoconstriction5.1 Pharmaceuticals6.1 PharmaceuticalsCancer cellMutationCancer researchNeoplasmDevelopment of treatments and therapeutic interventionsbusinessmedicine.drug
researchProduct

An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorecta…

2014

Abstract Author Summary Background. Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) are believed to mediate angiogenesis in colorectal cancer (CRC). Ramucirumab (RAM; IMC-1121B) is a human IgG1 monoclonal antibody that inhibits VEGF ligand binding to VEGFR-2, inhibiting VEGFR-2 activation and signaling. Methods. Patients with metastatic CRC, Eastern Cooperative Oncology Group performance status 0–1, and adequate organ function who had not received chemotherapy for metastatic disease received RAM and the modified FOLFOX-6 regimen every 2 weeks. Endpoints included progression-free survival (PFS), objective response rate, overall survival, and safety. The sample size wa…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyOrganoplatinum CompoundsAngiogenesisColorectal cancerLeucovorinAntibodies Monoclonal HumanizedDisease-Free SurvivalDrug Administration ScheduleRamucirumabchemistry.chemical_compoundAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm Metastasisbusiness.industryClinical Trial ResultsAntibodies MonoclonalKinase insert domain receptormedicine.diseaseVascular Endothelial Growth Factor Receptor-2Vascular endothelial growth factorVascular endothelial growth factor ATreatment OutcomeOncologychemistryFluorouracilMonoclonalCancer researchFluorouracilbusinessColorectal Neoplasmsmedicine.drugProtein Binding
researchProduct

Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.

2011

Abstract VEGF antagonists are now widely used cancer therapeutics, but predictive biomarkers of response or toxicity remain unavailable. In this study, we analyzed the effects of anti-VEGF therapy on tumor metabolism and therapeutic response by using an integrated set of imaging techniques, including bioluminescence metabolic imaging, 18-fluorodeoxyglucose positron emission tomography, and MRI imaging and spectroscopy. Our results revealed that anti-VEGF therapy caused a dramatic depletion of glucose and an exhaustion of ATP levels in tumors, although glucose uptake was maintained. These metabolic changes selectively accompanied the presence of large necrotic areas and partial tumor regress…

Vascular Endothelial Growth Factor ACancer Researchmedicine.medical_specialtyMagnetic Resonance SpectroscopyGlucose uptakeBiologyMiceFluorodeoxyglucose F18Internal medicineCell Line TumormedicineAnimalsHumansGlycolysisViability assayProtein kinase AAdenylate KinaseAMPKCancerNeoplasms Experimentalmedicine.diseaseWarburg effectMagnetic Resonance ImagingEndocrinologyPhenotypeOncologyCancer researchTumor necrosis factor alphaGlycolysisCancer research
researchProduct

Arthrinins A–D: Novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.

2011

Bioassay-guided fractionation of a methanolic extract of the fungus Arthrinium sp., isolated from the Mediterranean sponge Geodia cydonium, afforded 10 natural products including five new diterpenoids, arthrinins A-D (1-4) and myrocin D (5). In addition, five known compounds were obtained, which included myrocin A (6), norlichexanthone (7), anomalin A (8), decarboxycitrinone (9) and 2,5-dimethyl-7-hydroxychromone (10). The structures of all isolated compounds were unambiguously elucidated based on extensive 1D and 2D NMR and HR-MS analyzes. The absolute configuration of arthrinins A-D (1-4) was established by the convenient Mosher method performed in NMR tubes and by interpretation of the R…

Vascular Endothelial Growth Factor AClinical BiochemistryPharmaceutical ScienceAntineoplastic AgentsBiochemistryMiceAscomycotaCell Line TumorNeoplasmsDrug DiscoveryAnimalsHumansMTT assayCytotoxicityProtein Kinase InhibitorsMolecular BiologyNeovascularization PathologicKinaseChemistryOrganic ChemistryTerpenoidIn vitroPoriferaEndothelial stem cellVascular endothelial growth factor ABiochemistryCell cultureMolecular MedicineDiterpenesProtein KinasesBioorganic & Medicinal Chemistry
researchProduct

VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer.

2010

Inflammation drives expression of VEGFR2, which is expressed on and drives growth of tumor cells in colitis-associated cancer.

Vascular Endothelial Growth Factor AColorectal cancerGene Expressionmedicine.disease_causechemistry.chemical_compoundMice0302 clinical medicineImmunology and AllergyDecoy receptorsCells CulturedMice Knockout0303 health sciencesMicroscopy ConfocalReverse Transcriptase Polymerase Chain ReactionDextran Sulfaterespiratory systemColitisImmunohistochemistry3. Good healthUp-RegulationVascular endothelial growth factorVascular endothelial growth factor A030220 oncology & carcinogenesisColonic Neoplasmscardiovascular systemcirculatory and respiratory physiologySignal TransductionSTAT3 Transcription FactorImmunologyBlotting WesternMice TransgenicBiologyArticle03 medical and health sciencesmedicineAnimalsHumans030304 developmental biologyCell ProliferationVascular Endothelial Growth Factor Receptor-1CancerEndothelial CellsKinase insert domain receptorEpithelial CellsCell Biologymedicine.diseaseInflammatory Bowel DiseasesVascular Endothelial Growth Factor Receptor-2Mice Inbred C57BLHIF1AchemistryCancer researchCarcinogenesis030215 immunologyThe Journal of experimental medicine
researchProduct

Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis

2011

Fibronectin (FN) is a major component of the extracellular matrix and functions in cell adhesion, cell spreading and cell migration. In the retina, FN is transiently expressed and assembled on astrocytes (ACs), which guide sprouting tip cells and deposit a provisional matrix for sprouting angiogenesis. The precise function of FN in retinal angiogenesis is largely unknown. Using genetic tools, we show that astrocytes are the major source of cellular FN during angiogenesis in the mouse retina. Deletion of astrocytic FN reduces radial endothelial migration during vascular plexus formation in a gene dose-dependent manner. This effect correlates with reduced VEGF receptor 2 and PI3K/AKT signalli…

Vascular Endothelial Growth Factor AIntegrinsAngiogenesisIntegrinNeovascularization PhysiologicMice TransgenicExtracellular matrixMicePhosphatidylinositol 3-KinasesCell MovementAnimalsProtein Interaction Domains and MotifsMolecular BiologyResearch ArticlesMice KnockoutSprouting angiogenesisbiologyRetinal VesselsCell migrationKinase insert domain receptorVascular Endothelial Growth Factor Receptor-2Extracellular MatrixFibronectinsCell biologyMice Inbred C57BLFibronectinVascular endothelial growth factor AAstrocytesbiology.proteinHeparitin SulfateOligopeptidesProto-Oncogene Proteins c-aktIntegrin alpha5beta1Signal TransductionDevelopmental BiologyDevelopment
researchProduct

Reactive oxygen species activation of MAPK pathway results in VEGF upregulation as an undesired irradiation response

2013

Background Radioresistance limits the effectiveness of radiotherapy in head and neck squamous cell carcinoma. We previously demonstrated post-radiogenic mitogen-activated protein kinase (MAPK) pathway activation and vascular endothelial growth factor (VEGF) release resulting in reduced tumor cell response. Here, we examined the association of this mechanism with the induction of reactive oxygen species (ROS) under irradiation (IR). Methods Intracellular ROS after IR were measured. We modeled radiation-induced ROS by exposure of two SCC lines to H2O2 and evaluated the impact of irradiation and ROS on ERK phosphorylation by Western blot, immunohistochemistry, and ELISA. Results We found eleva…

Vascular Endothelial Growth Factor AMAPK/ERK pathwayCancer ResearchPathologymedicine.medical_specialtyMAP Kinase Signaling SystemBlotting WesternEnzyme-Linked Immunosorbent AssayBiologyRadiation TolerancePathology and Forensic Medicinechemistry.chemical_compoundDownregulation and upregulationCell Line TumorNitrilesButadienesmedicineHumansEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesProtein kinase Achemistry.chemical_classificationReactive oxygen speciesHydrogen PeroxideImmunohistochemistryCytoprotectionUp-RegulationVascular endothelial growth factorVascular endothelial growth factor AOtorhinolaryngologychemistryCytoprotectionCarcinoma Squamous CellCancer researchPeriodonticsElectrophoresis Polyacrylamide GelOral SurgeryReactive Oxygen SpeciesIntracellularJournal of Oral Pathology & Medicine
researchProduct

Activation of mitogen-activated protein kinase extracellular signal-related kinase in head and neck squamous cell carcinomas after irradiation as par…

2010

Background. Irradiation plays a pivotal role in head and neck squamous cell carcinoma (HNSCC) treatment. However, especially recurrent tumors frequently show increased radioresistance. We analyzed irradiation-stimulated mitogen-activated protein kinase (MAPK) signaling pathways to define cellular rescue mechanisms. Methods. Irradiated HNSCC cells were screened for MAPK activation and results were confirmed and refined by functional analyses. Extracellular signal-regulated kinase (ERK) inhibitor U0126 application enabled us to specify postradiogenic cellu- lar responses. Vascular endothelial growth factor (VEGF) levels were analyzed additionally. Results. We observed a pronounced and time-de…

Vascular Endothelial Growth Factor AMAPK/ERK pathwayMAP Kinase Signaling SystemMice NudeMicechemistry.chemical_compoundCell Line TumorRadioresistanceNitrilesButadienesmedicineAnimalsHumansEnzyme InhibitorsExtracellular Signal-Regulated MAP KinasesProtein kinase AbiologyKinasebusiness.industryRadiotherapy Dosagemedicine.diseaseImmunohistochemistryHead and neck squamous-cell carcinomaUp-RegulationVascular endothelial growth factorOtorhinolaryngologychemistryHead and Neck NeoplasmsMitogen-activated protein kinaseCarcinoma Squamous CellCancer researchbiology.proteinMitogen-Activated Protein KinasesSignal transductionbusinessNeoplasm TransplantationSignal TransductionHead & Neck
researchProduct

Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond

2017

Cardiotoxicity induced by chemotherapeutic agents and radiotherapy is a growing problem. In recent years, an increasing number of new drugs with targeted action have been designed. These molecules, such as monoclonal antibodies and tyrosine kinase inhibitors, can cause different type of toxicities compared to traditional chemotherapy. However, they can also cause cardiac complications such as heart failure, arterial hypertension, QT interval prolongation and arrhythmias. Currently, a field of intense research is the vascular toxicity induced by new biologic drugs, particularly those which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGF-R) and other tyrosine kinases.…

Vascular Endothelial Growth Factor APathologymedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentVascular toxicity VEGF cardiotoxicity new target therapy chemotherapy radiotherapy cardio-oncologyAntineoplastic Agents030204 cardiovascular system & hematologyQT intervalCardiooncology03 medical and health scienceschemistry.chemical_compoundCardio-oncology; Cardiotoxicity; Chemotherapy; New target therapy; Radiotherapy; Vascular toxicity; VEGF; Medicine (all); Cardiology and Cardiovascular Medicine0302 clinical medicineVascularReceptorsmedicineAnimalsHumansChemotherapyEndotheliumNew target therapyChemotherapyCardiotoxicityRadiotherapybusiness.industryVascular Endothelial Growth FactorMedicine (all)Cardiooncology; Vascular toxicity; New target therapyCardio-oncology; Cardiotoxicity; Chemotherapy; New target therapy; Radiotherapy; Vascular toxicity; VEGF; Animals; Antineoplastic Agents; Cardiotoxicity; Endothelium Vascular; Heart Diseases; Humans; Reactive Oxygen Species; Receptors Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Amedicine.diseaseVEGFCardiotoxicityVascular endothelial growth factorRadiation therapyCardio-oncologyVascular endothelial growth factor AReceptors Vascular Endothelial Growth Factorchemistry030220 oncology & carcinogenesisHeart failureCancer researchEndothelium VascularVascular toxicityReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessTyrosine kinaseInternational Journal of Cardiology
researchProduct